Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Name||head and neck carcinoma|
|Definition||A head and neck cancer that has_material_basis_in epithelial cells and is located in the upper aerodigestive tract, including the lip, oral cavity (mouth), nasal cavity, paranasal sinuses, pharynx, and larynx.|
|Path||disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|FGFR1 amp||Infigratinib||head and neck carcinoma||predicted - sensitive||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02723955||Phase I||GSK3359609 GSK3359609 + Pembrolizumab||Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)||Active, not recruiting||USA | ITA | FRA | ESP | CAN||4|
|NCT03693014||Phase II||A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors||Recruiting||USA||0|
|NCT03727061||Phase II||Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab||Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer||Recruiting||USA||0|
|NCT04140526||Phase Ib/II||ONC-392 ONC-392 + Pembrolizumab||Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC||Recruiting||USA||0|
|NCT05259319||Phase I||Atezolizumab + Tiragolumab||Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)||Not yet recruiting||FRA||0|